114 The utilisation patterns of Systemic Anti-Cancer Therapy (SACT) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) in England
No Thumbnail Available
Authors
Lauren Kari D.
Adrian C.
Ella B.
Joanne B.
Douglas W.
John C.
Neal N.
David,C.
Contact
Check for full-text access
Issue Date
2025
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background National guidelines recommend that people with advanced stage non-small cell lung cancer (NSCLC) and good performance status (PS 0-1) are offered Systematic Anti-Cancer Therapy (SACT). The aim of this study is to investigate patterns of SACT use among patients with advanced NSCLC within England. Methods Patients with newly-diagnosed stage IIIB-IV NSCLC in England in 2019-2022 were identified from the national Rapid Cancer Registration Dataset (which includes data received directly from the SACT dataset). Associations between treatment and patient characteristics were analysed using multivariate logistic regression. Empirical Bayes estimates of treatment rates were used to analyse variation in SACT utilisation between cancer alliances. The effect of treatment on survival was used to estimate potential life-years gained by an increase in treatment rates. Results We analysed 60,210 patients diagnosed with advanced NSCLC in England (2019-2022). PS was scored as good (0-1) in 26,055 patients; of these, 62% (n = 16,155) received SACT. Age (odds ratio (OR) for?>85yrs vs <55yrs = 0.31, 95%CI 0.28-0.34), frailty (OR for severe frailty vs none/mild = 0.61, 95%CI 0.56-0.67) and social deprivation (OR for most vs least deprived = 0.85, 95%CI 0.80-0.89) were strong predictors of treatment after adjustment for disease stage and comorbidity score. Treatment rates varied between cancer alliances (min-max = 51%-72%), with lower rates significantly associated with poorer survival (p = 0.003). If all cancer alliances matched the highest treatment rate (72%), a further 448 patients would be treated each year, with an estimated 289 life-years gained. Conclusion Among patients with advanced NSCLC and good performance, use of SACT is associated with age, frailty and socioeconomic deprivation. Increasing rates of use among cancer alliances with low rates could lead to additional life-years gained within this population. Disclosure No significant relationships. [Formula presented]
Description
Citation
Publisher
License
Journal
Lung Cancer (Amsterdam, Netherlands)
Volume
Issue
Poster abstracts of the 23rd Annual British Thoracic Oncology Group Conference 2025.